FDA Rejects Nuplazid Application for Treatment of Alzheimer’s Disease Psychosis
The FDA has rejected an application to approve Nuplazid to treat Alzheimer's disease psychosis.
Tag Archives: Atypical Antipsychotic
-
-
FDA Rejects Request To Expand Nuplazid Use For Symptoms of Dementia-Related Psychosis
Federal health regulators have rejected an application filed by Acadia Pharmaceuticals to expand the use of its blockbuster antipsychotic drug, Nuplazid, highlighting concerns that the medication may not be effective…
-
ISMP Report Questions Nuplazid Safety, FDA Approval And Lack Of Warnings
An ISMP report questions the FDA conclusions that there are no new safety signals with the Parkinson's disease psychosis drug, Nuplazid.
-
Rexulti Gambling Risks Lead to Concerns About Abilify Replacement Drug
New warnings have been added to the warning label for the antipsychotic Rexulti, warning that it carries a risk of gambling addiction, similar to claims made regarding the drug Abilify.
-
Nuplazid Safety Risks May Lead FDA To Re-Review New Medication, Gottlieb Tells Senate
The FDA has launched a new safety review of the Parkinson's disease drug Nuplazid, FDA Commissioner Scott Gottlieb told Congress last week.
-
Nuplazid Problems Linked To Hundreds Of Patient Deaths: Report
More than 700 deaths have been linked to Nuplazid side effects, raising concerns about the safety of the Parkinson's disease drug.
-
Geodon Side Effects Linked To Potentially Deadly Skin Reactions: FDA
The FDA is warning that side effects of Geodon and generic equivalents of the antipsychotic medication may cause a rare but serious skin reaction known as Drug Reaction with Eosinophilia…
